Chronic inducible urticaria (CIndU) includes different chronic urticaria subtypes that are inducible by specific triggers. Evidence exists that CIndU appears to be more resistant to standard doses of antihistamines than chronic spontaneous urticaria (CSU), and with only one approved biological therapy targeting CSU—Novartis/Roche’s Xolair—CIndU presents an opportunity for more-effective drug development. Although patient shares of drug classes have been relatively stable over the last year, positive trends among more-recent second-generation antihistamines can be seen with improved efficacy and fewer side effects. Montelukast is a key drug in the CIndU market and a preferred combination agent, consistent with the recommended use of leukotriene receptor antagonists as add-on treatment in the current urticaria treatment guidelines. Biologics such as AbbVie’s Humira and Xolair see off-label use for CIndU patients, underscoring the need for novel therapies in this space.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed CIndU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CIndU patients?
- How have TNF-alpha inhibitors and Xolair been integrated into the treatment algorithm?
- What proportion of CIndU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of CIndU patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with CIndU?